arrow
F

Federica Martorana

University of Catania
H指数:16
被引数:1,400

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Revisiting diffuse gliomas in the era of precision medicine: Molecular insights and therapeutic implications

在精准医学时代重新审视弥漫性胶质瘤:分子洞察和治疗意义

2026-08-010
PRE
Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study
2026-06-240
OAAI
Preclinical Rationale, Clinical Efficacy, and Safety of the Selective AKT Kinase Inhibitor Capivasertib in Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Carcinoma: A Practical Narrative Review

临床前理论依据、临床疗效及选择性AKT激酶抑制剂Capivasertib在转移性激素受体阳性、人表皮生长因子受体2阴性乳腺癌中的安全性:一项实用性叙事综述

2026-04-040
OAAI
Survival and Extent of Breast Surgery in Patients with Complete Response After Neoadjuvant Therapy: A Retrospective Analysis from the EUSOMA Database

新辅助治疗后完全缓解患者的乳腺癌手术生存率及手术范围:EUSOMA数据库的回顾性分析

Cancers
IF4.4
2026-01-010
OA
Association of Neoadjuvant Chemotherapy Dose Intensity with Pathological Complete Response and Event-Free Survival in HER2-Negative Early Breast Cancer

新辅助化疗剂量强度与HER2阴性早期乳腺癌病理完全缓解及无事件生存期的关系

2025-11-120
PRE
RSC4All as a machine learning nomogram to predict RSClin™ results in HR+/HER2- node-negative early breast cancer

RSC4All 作为一种机器学习列线图,用于预测 HR+/HER2- 淋巴结阴性早期乳腺癌的 RSClin™ 结果

2025-10-070
OAAI
Unlocking the Potential of Immune Checkpoint Inhibitors in HR+/HER2− Breast Cancer: A Systematic Review

解锁免疫检查点抑制剂在HR+/HER2−乳腺癌中的潜力:一项系统综述

2025-09-230
OAAI
Clinico-pathological features predicting indication to mastectomy in breast cancer patients achieving complete response after neoadjuvant therapy: A retrospective analysis of the EUSOMA database

临床病理特征预测乳腺癌患者在新辅助治疗后获得完全缓解的乳房切除术指征: 对EUSOMA数据库的回顾性分析

EJSO
IF2.9
2025-06-011
PRE